Market capitalization | $1.48m |
Enterprise Value | $9.50m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-14.72m |
Free Cash Flow (TTM) Free Cash Flow | $-12.51m |
EPS (TTM) EPS | $-15,420.51 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Biophytis - ADR:
1 Analyst has issued a forecast Biophytis - ADR:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.87 -0.87 |
74%
74%
|
|
EBITDA | -14 -14 |
30%
30%
|
EBIT (Operating Income) EBIT | -15 -15 |
28%
28%
|
Net Profit | -16 -16 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biophytis SA is a holding company. It engages in the clinical development of therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. The firm develops drug candidates targeting diseases of aging. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 15, 2006 and is headquartered in Paris, France.
Head office | France |
CEO | Stanislas Veillet |
Founded | 2006 |
Website | www.biophytis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.